A股異動 | 天宜上佳(688033.SH)續漲9% 績後獲券商看好
格隆匯8月6日丨天宜上佳(688033.SH)股價繼續走強,現報25.24元創逾一年新高,漲幅9.12%,最新總市值113.3億,年內累計漲幅逾70%。公司昨日公吿稱,今年上半年實現營業收入2.23億元,同比增長56.75%;歸屬於上市公司股東的淨利潤5640.38萬元,同比增長48.07%。中信建投指,公司業績符合預期,綜合考慮公司技術領先性、產品耗材屬性以及新業務未來成長性,公司2021-2023年有望保持高速增長,按照PEG=1,給予天宜上佳2022年35倍估值,目標價32.0元,維持“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.